The de-SPAC completion provides XLAB with public market access and ~$12.9M in pro forma cash, but the going-concern qualification and ongoing net losses signal high cash-burn risk. Monitor revenue growth trajectory and path to profitability. The six-month lock-up expiration (late February 2027) could introduce selling pressure from former Exascale holders holding ~77.7% of shares. The 14.1M warrants at $11.50 are out of the money at the implied ~$5.69 per share based on market cap.
Price Chart
Executive Summary
Exascale Labs Holdings Inc. (XLAB) completed its de-SPAC business combination on August 27, 2026, merging BCAR (SPAC) with Exascale Labs Inc. The combined entity began trading on Nasdaq under XLAB (Class A common) and XLABW (warrants). The merger consideration was $500M in stock, with 64.3M shares outstanding post-close. Pro forma financials show $10.6M revenue for the nine months ended March 31, 2026, a net loss of $3.5M, and a going-concern qualification in the historical audited financials. The company also changed auditors, adopted a new equity incentive plan, and implemented lock-up agreements for former Exascale holders.
Key Financial Metrics
Key Facts
- Business combination closed on August 27, 2026; BCAR ceased to be a shell company
- Merger consideration of $500,000,000 paid in 50,000,000 shares of PubCo common stock at $10.00 per share
- Post-combination: 64,334,789 shares outstanding (33,689,050 Class A + 30,645,739 Class B); Class B shares carry 20 votes each
- Pro forma revenue $10,561,331 for nine months ended March 31, 2026; pro forma net loss $3,469,636
- Pro forma loss per share of ($0.054) for nine months ended March 31, 2026 and ($0.065) for year ended June 30, 2025
- 14,099,992 warrants outstanding, exercisable at $11.50 per share
- Lock-up agreements for former Exascale stockholders and SAFE holders for six months from closing
- Auditor changed: Guangdong Prouden CPAs GP dismissed; HTL International, LLC appointed
- Going-concern qualification in BCAR's audited financial statements
- Adopted 2026 Omnibus Equity Incentive Plan with 10,000,000 shares initially reserved
- Fiscal year changed from December 31 to June 30
Financial Impact
Merger consideration of $500M in stock; pro forma cash of $12.9M; pro forma net loss of $3.5M on $10.6M revenue
Risk Factors
- Going-concern qualification in historical audited financials
- Significant net losses and negative operating cash flow
- Dilution from 14.1M warrants and equity incentive plan (10M shares + annual increases)
- Lock-up expiration in ~6 months could create selling pressure
- Limited operating history as a public company; new management team
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-009632 |
| Exhibit: exascalelabs_ex99-1.htm | 0001829126-26-009632 |
| Exhibit: exascalelabs_8k.htm | 0001829126-26-009632 |
| Exhibit: exascalelabs_ex10-4.htm | 0001829126-26-009632 |
| Exhibit: exascalelabs_ex3-1.htm | 0001829126-26-009632 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | SC 13G | $2.35 $3.35 | ▲ +42.55% | ▲ +42.98% | $3.39 (+44.26%) |
Oct 14, 2026 12d ago | 8-K | $1.36 $4.71 | ▲ +246.32% | ▲ +247.34% | $3.39 (+149.26%) |
Sep 30, 2026 26d ago | 8-K | $1.47 $1.02 | ▼ −30.61% | ▼ −31.91% | $3.39 (+130.61%) |
Sep 28, 2026 28d ago | Press Release | $2.07 $1.08 | ▼ −47.83% | ▼ −49.77% | $3.39 (+63.77%) |
Sep 2, 2026 7w ago | 8-K | $4.04 $4.22 | ▲ +4.46% | ▲ +5.41% | $3.39 (−16.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers